FDA Grants Orphan Drug Status for Cephalon's Lestaurtinib
FDA Grants Orphan Drug Status for Cephalon's Lestaurtinib
FRAZER, PennsylvaniaThe FDA has granted orphan drug status to Cephalon, Inc.'s lestaurtinib (CEP-701) for acute myeloid leukemia (AML). The oral compound inhibits several tyrosine kinases including FLT-3 and TrkA. It is in phase II/III trials for AML patients at first relapse who have a FLT-3 activating mutation.
Articles in this issue
NCCN Soft-Tissue Extremity Sarcoma Guidelines Clarify Follow-up Schedule
Genentech Files sBLA for Avastin for First-Line NSCLC Treatment
RFA Effective for Single, Small Hepatocellular Carcinoma
New Imaging, ChemoRT Recommendations From NCCN
Panitumumab Improves PFS in Advanced Colon Ca
Studies Question Watchful Waiting for Some Prostate Ca Pts
Growing Evidence Supports Stem Cell Hypothesis of Cancer
FDA Approves New Every-3-Week Dosing for Aranesp
Telephone Often Delivers News of Breast Cancer Diagnosis
IND Submitted for CYT-500
Lower-Dose Thalidomide Effective in Relapsed or Refractory Multiple Myeloma, With Less Toxicity
Zometa Increases BMD in Breast Ca Patients on Femara
Prostate Cancer Recurrence Linked to Surgeon's Skill
FDA Grants Orphan Drug Status for Cephalon's Lestaurtinib
Automated Voice System Manages Chemo Symptoms
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
